Search

Displaying results 2591 - 2600 of 7018 in total
  1. Drug

    Inula helenium root

    go.drugbank.com/drugs/DB14350
    Approved

    Inula helenium root is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

  2. Drug

    Alatrofloxacin

    go.drugbank.com/drugs/DB09335
    ApprovedWithdrawn

    Alatrofloxacin is a fluoroquinolone antibiotic developed by Pfizer, delivered as a mesylate salt. It was withdrawn from the U.S. market in 2001.

  3. Drug

    Abametapir

    go.drugbank.com/drugs/DB11932
    Approved

    a potential therapeutic target. … [A216183] Topical pediculicides generally lack adequate ovicidal activity,[A216183] including standard-of-care treatments such as [permethrin], and many require a second administration 7-10 days following

  4. Drug

    Bird pepper

    go.drugbank.com/drugs/DB14262
    Approved

    Bird pepper is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

  5. Drug

    Milk thistle

    go.drugbank.com/drugs/DB14375
    ApprovedInvestigational

    Milk thistle is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

  6. Drug

    Synthetic Conjugated Estrogens, B

    go.drugbank.com/drugs/DB09318
    Approved

    Conjugated Equine Estrogens (CEEs) are derived from the urine of pregnant mares and contain a blend of at least 10 estrogen derivatives. … There is currently no generic form of CEEs available as a detailed analytical characterization of the active ingredients or of their estrogenic activity is not available at this time.

  7. Drug

    Lunsotogene parvec

    go.drugbank.com/drugs/DB18278
    ApprovedInvestigational

    [L56135,L56136] This landmark decision followed designations as a Regenerative Medicine Advanced Therapy (RMAT) and Fast Track, marking the first-ever gene therapy approved to restore a neurosensory function … Lunsotogene parvec is a first-in-class dual adeno-associated virus serotype 1 vector-based gene therapy developed to address an unmet medical need for OTOF-related sensorineural hearing loss.

  8. Drug

    Canakinumab

    go.drugbank.com/drugs/DB06168
    ApprovedInvestigational

    Both heavy chains of canakinumab contain oligosaccharide chains linked to the protein backbone at asparagine 298 (Asn 298). … It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated.

  9. Drug

    Ensartinib

    go.drugbank.com/drugs/DB14860
    ApprovedInvestigational

    [A273963, A273958] Ensartinib is a first-line treatment for anaplastic lymphoma kinase (ALK)-mutated non-small cell lung cancer (NSCLC). … [A273968] Chemically, ensartinib is an aminopyridazine-based, small molecule tyrosine kinase inhibitor (TKI) which inhibits the anaplastic lymphoma kinase (ALK) protein.

  10. Drug

    Anthrax immune globulin human

    go.drugbank.com/drugs/DB09057
    ApprovedInvestigational

    Available as the product Anthrasil (FDA), the result is a solution for slow IV infusion containing polyclonal antibodies that bind the protective antigen (PA) component of Bacillus anthracis lethal and … Anthrax immune globulin is a human antibody given with antibiotics for the treatment of anthrax.